Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically. The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and safety profile of radiotherapy combined with ipil...

Full description

Saved in:
Bibliographic Details
Main Authors: Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000627.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items